Alembic Pharmaceuticals Limited (BOM:533573)
935.05
-15.15 (-1.59%)
At close: Aug 8, 2025
Marinus Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 17.11B INR in the quarter ending June 30, 2025, with 9.54% growth. This brings the company's revenue in the last twelve months to 68.21B, up 8.20% year-over-year. In the fiscal year ending March 31, 2025, Alembic Pharmaceuticals had annual revenue of 66.72B with 7.12% growth.
Revenue (ttm)
68.21B
Revenue Growth
+8.20%
P/S Ratio
2.70
Revenue / Employee
4.12M
Employees
16,571
Market Cap
184.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 66.72B | 4.43B | 7.12% |
Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,429.39B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
Alembic Pharmaceuticals News
- 4 days ago - Alembic Pharma share: Antique maintains buy, raises target to Rs 1,275 on US growth outlook - Business Upturn
- 15 days ago - Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets - Business Upturn
- 5 weeks ago - Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence - Business Upturn
- 5 weeks ago - Alembic Pharma share jump 3% after company gets US FDA approval for Doxorubicin Hydrochloride Injection - Business Upturn
- 7 weeks ago - Alembic Pharma receives EIR from USFDA for Karakhadi API-III facility - Business Upturn
- 7 weeks ago - Pharma stocks in focus as Trump announces tariffs on sector ‘soon’ - Business Upturn
- 2 months ago - Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility - Business Upturn
- 2 months ago - Alembic Pharmaceuticals shares in focus after USFDA nod for cancer drug Bosutinib - Business Upturn